Network insights on oxaliplatin anti-cancer mechanisms

被引:27
作者
Alian, Osama M. [1 ]
Azmi, Asfar S. [2 ]
Mohammadl, Ramzi M. [1 ,3 ]
机构
[1] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, 4100 John R,HWCRC,Room 732, Detroit, MI 48201 USA
[2] Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA
[3] Hamad Med Corp, Doha, Qatar
关键词
Oxaliplatin; Chemotherapy; Resistance signatures; Systems biology; Network theory; Network modeling;
D O I
10.1186/2001-1326-1-26
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Oxaliplatin has been a crucial component of combination therapies since admission into the clinic causing modest gains in survival across multiple malignancies. However, oxaliplatin functions in a non-targeted manner, posing a difficulty in ascertaining precise efficacy mechanisms. While previously thought to only affect DNA repair mechanisms, Platinum-protein adducts (Pt-Protein) far outnumber Pt-DNA adducts leaving a big part of oxaliplatin function unknown. Through preliminary network modeling of high throughput data, this article critically reviews the efficacy of oxaliplatin as well as proposes a better model for enhanced efficacy based on a network approach. In our study, not only oxaliplatin's function in interrupting DNA-replication was confirmed, but also its role in initiating or intensifying tumorigenesis pathways was uncovered. From our data we present a novel picture of competing signaling networks that collectively provide a plausible explanation of chemotherapeutic resistance, cancer stem cell survival, as well as invasiveness and metastases. Here we highlight oxaliplatin signaling networks, their significance and the clinical implications of these interactions that verifies the importance of network modeling in rational drug design.
引用
收藏
页数:7
相关论文
共 30 条
[1]   Opinion - Survivin, cancer networks and pathway-directed drug discovery [J].
Altieri, Dario C. .
NATURE REVIEWS CANCER, 2008, 8 (01) :61-70
[2]  
Azmi AS, 2011, ONCOTARGET, V2, P378
[3]   Proof of Concept: Network and Systems Biology Approaches Aid in the Discovery of Potent Anticancer Drug Combinations [J].
Azmi, Asfar S. ;
Wang, Zhiwei ;
Philip, Philip A. ;
Mohammad, Ramzi M. ;
Sarkar, Fazlul H. .
MOLECULAR CANCER THERAPEUTICS, 2010, 9 (12) :3137-3144
[4]   RETRACTED: Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells (Retracted article. See vol. 423, pg. 153, 2018) [J].
Bao, Bin ;
Wang, Zhiwei ;
Ali, Shadan ;
Kong, Dejuan ;
Li, Yiwei ;
Ahmad, Aamir ;
Banerjee, Sanjeev ;
Azmi, Asfar S. ;
Miele, Lucio ;
Sarkar, Fazlul H. .
CANCER LETTERS, 2011, 307 (01) :26-36
[5]   Network analyses in systems pharmacology [J].
Berger, Seth I. ;
Iyengar, Ravi .
BIOINFORMATICS, 2009, 25 (19) :2466-2472
[6]   Notch signalling: a simple pathway becomes complex [J].
Bray, Sarah J. .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2006, 7 (09) :678-689
[7]   Exploring metallodrug-protein interactions by ESI mass spectrometry: The reaction of anticancer platinum drugs with horse heart cytochrome c [J].
Casini, Angela ;
Gabbiani, Chiara ;
Mastrobuoni, Guido ;
Messori, Luigi ;
Moneti, Gloriano ;
Pieraccini, Giuseppe .
CHEMMEDCHEM, 2006, 1 (04) :413-417
[8]   Protein interactions with platinum-DNA adducts: from structure to function [J].
Chaney, SG ;
Campbell, SL ;
Temple, B ;
Bassett, E ;
Wu, YB ;
Faldu, M .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2004, 98 (10) :1551-1559
[9]   VILIP-1 Downregulation in Non-Small Cell Lung Carcinomas: Mechanisms and Prediction of Survival [J].
Fu, Jian ;
Fong, Kathryn ;
Bellacosa, Alfonso ;
Ross, Eric ;
Apostolou, Sinoula ;
Bassi, Daniel E. ;
Jin, Fang ;
Zhang, Jirong ;
Cairns, Paul ;
Ibanez de Caceres, Immaculada ;
Braunewell, Karl-Heinz ;
Klein-Szanto, Andres J. .
PLOS ONE, 2008, 3 (02)
[10]   Oxaliplatin [J].
Graham, J ;
Muhsin, M ;
Kirkpatrick, P .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (01) :11-12